ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Kineta Inc

Kineta Inc (KA)

0.6017
-0.0083
( -1.36% )
Updated: 13:15:51

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.6017
Bid
0.59
Ask
0.61
Volume
17,643
0.59 Day's Range 0.613781
0.3339 52 Week Range 5.39
Market Cap
Previous Close
0.61
Open
0.6099
Last Trade
35
@
0.5901
Last Trade Time
13:22:00
Financial Volume
$ 10,599
VWAP
0.600733
Average Volume (3m)
400,882
Shares Outstanding
10,393,567
Dividend Yield
-
PE Ratio
-1.39
Earnings Per Share (EPS)
-1.36
Revenue
5.44M
Net Profit
-14.1M

About Kineta Inc

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy. Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Kineta Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KA. The last closing price for Kineta was $0.61. Over the last year, Kineta shares have traded in a share price range of $ 0.3339 to $ 5.39.

Kineta currently has 10,393,567 shares outstanding. The market capitalization of Kineta is $19.64 million. Kineta has a price to earnings ratio (PE ratio) of -1.39.

KA Latest News

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any...

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...

Kineta Announces Restructuring and Exploration of Strategic Alternatives

SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.081715.71153846150.520.73990.50753262900.63854317CS
40.071413.46407693760.53030.73990.33398665480.50557441CS
12-1.9783-76.67829457362.582.830.33394008820.59852474CS
26-2.7983-82.30294117653.44.90.33391980580.75601819CS
52-3.3983-84.957545.390.33391105430.98862757CS
156-8.2783-93.22409909918.8890.3339903421.41250301CS
260-8.2783-93.22409909918.8890.3339903421.41250301CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAUDCollective Audience Inc
$ 0.72
(84.62%)
144.14M
DCPHDeciphera Pharmaceuticals Inc
$ 25.22
(72.15%)
41.26M
MULNMullen Automotive Inc
$ 4.989
(57.88%)
44.19M
CSLRComplete Solaria Inc
$ 0.5866
(54.00%)
10.4M
HWHHWH International Inc
$ 2.57
(41.21%)
23.85M
CLVRClever Leaves Holdings Inc
$ 1.61
(-60.83%)
640.87k
ADXNAddex Therapeutics Ltd
$ 8.00
(-50.31%)
132.61k
MFImF International Ltd
$ 1.55
(-33.48%)
2.61M
TSDDGraniteShares ETF Trust GraniteShares
$ 17.15
(-31.12%)
1.27M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 27.14
(-30.89%)
6.46M
TSLATesla Inc
$ 194.3501
(15.49%)
181.66M
SINTSiNtx Technologies Inc
$ 0.055
(36.14%)
146.13M
CAUDCollective Audience Inc
$ 0.72
(84.62%)
144.14M
SOFISoFi Technologies Inc
$ 7.1298
(-9.41%)
117.47M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 9.38
(31.19%)
69.24M

KA Discussion

View Posts
INV4 INV4 1 week ago
Thanks Gail!

HOD 0.74 so far today 😃

$KA
๐Ÿ‘๏ธ0
gail gail 1 week ago
its up 17% so โ€ฆโ€ฆ

โ€ฆ.

far today it shows, so im happy for you.
👍️ 1
INV4 INV4 1 week ago
Ok lol 😄 Well I like the Float (6.59M) / OS (10.96M).

(I've seen such an $8 price target with $OCEA when it was trading at $0.50 cents or something and it hit $7.79. I took a small starter here... Whatever happens, it's all good).

KINETA INC (KA):
Shares Outstanding 10.96M
Shares Change (YoY) +124.40%
Shares Change (QoQ) +8.20%
Owned by Insiders (%) 29.25%
Owned by Institutions (%) 12.05%
Float 6.59M

GLTY

$KA
๐Ÿ‘๏ธ0
gail gail 1 week ago
moved on to bigger and better things, lol
๐Ÿ‘๏ธ0
INV4 INV4 1 week ago
Have you seen this price target? I don't know if that target is realistic/achievable here?

================

Kineta (KA) Price Target Increased by 25.58% to 13.77
April 17, 2024 โ€” 08:19 pm EDT

The average one-year price target for Kineta (NasdaqCM:KA) has been revised to 13.77 / share. This is an increase of 25.58% from the prior estimate of 10.96 dated March 28, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 13.64 to a high of 14.18 / share. The average price target represents an increase of 2,770.54% from the latest reported closing price of 0.48 / share.

https://www.nasdaq.com/articles/kineta-ka-price-target-increased-by-25.58-to-13.77

$KA
๐Ÿ‘๏ธ0
gail gail 2 weeks ago
in a good way? i see we are moving up now.
๐Ÿ‘๏ธ0
Awl416 Awl416 2 weeks ago
Watch out
๐Ÿ‘๏ธ0
Awl416 Awl416 3 weeks ago
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
KA new 52 week lo
๐Ÿ‘๏ธ0
AJ Freely AJ Freely 9 months ago
$KA - Up 7% Pre-Market/ Current Price $2.48
To Receive $5 Million Milestone Payment from Merck & eligible to receive additional milestone payments totaling up to $255m associated with the successful development of marketed products for pipeline program | 6/20.23
๐Ÿ‘๏ธ0
makinezmoney makinezmoney 1 year ago
$KA : Here you go............


https://investorshub.advfn.com/Starry-GROUP-Holdings-41712

Merr Christmas



GO $KA
๐Ÿ‘๏ธ0
tw0122 tw0122 1 year ago
Can you get them to open up comments on STRY you have clout.. Lol up over 1,436 percent biggest runner today..

Starry got delisted
๐Ÿ‘๏ธ0
makinezmoney makinezmoney 1 year ago
$KA: ReverseMerger with Yumanity Thera completed


https://kinetabio.com/

Added 10k here at $4.50 !!!!!!!!!!


LETS GOOooooooooooooooooooooooooooooooooo


The Company
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patientsโ€™ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kinetaโ€™s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies.
Kineta has established its immuno-oncology focused platform aimed at developing fully human antibodies to address the major mechanisms of cancer immune resistance. With drug candidates expected to enter the clinic and additional immuno-oncology assets in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.

Kineta has assembled an experienced management team, a seasoned research and development team, an immuno-oncology focused scientific advisory board, an enabling technology platform and a leading intellectual property position to advance its pipeline of potential novel immunotherapies for cancer patients.


GO $KA
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock